Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential is a funding call from European Commission – Horizon Europe that closes 17 February 2027 (forthcoming — not yet open). Funding: EUR 9,000,000–11,000,000 per project. Eligibility: Collaborative Horizon Europe project: legal entities in EU Member States or associated countries, normally as a consortium (standard Horizon Europe eligibility, Annex B). Status: forthcoming — submission not yet open.
- Funder
- European Commission – Horizon Europe
- Deadline
- 17 Feb 2027 (125 days)
- Status
- Forthcoming
- Amount
- EUR 9,000,000–11,000,000 per project
- Region / eligibility
- EU Member States & Horizon Europe associated countries
- Career stage
- established / PI
- Fields
- chemistry, pharma process
- Reference
- HORIZON-HLTH-2027-01-DISEASE-05
- Official call
- EU Funding & Tenders listing
Eligibility in plain language
Collaborative Horizon Europe project: legal entities in EU Member States or associated countries, normally as a consortium (standard Horizon Europe eligibility, Annex B). Status: forthcoming — submission not yet open.
Who should apply
Synthetic, physical and analytical chemists, medicinal chemists and pharma process / drug-development teams — best fit for PIs and research groups able to join or build a multi-country consortium.
Summary from source
Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: The scientific and clinical communities have a better understanding of and access to experimental antivirals for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation. Candidate antiviral therapies are available to treat patients for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic. Scope: Infectious diseases remain a major threat to health and health security in the EU and globally. Viral…